A UC Berkeley study found that combining oxytocin with an Alk5 inhibitor extended lifespan by 70% in frail elderly male mice. Benefits were sex-specific — females showed no lasting improvement. Here's what the data says and whether it could reach humans.
Eli Lilly signed a $2.75B deal with Insilico Medicine for AI-generated drug candidates targeting age-related diseases. Big Pharma is now investing billions in longevity drug discovery. Here's what it means for clinics and patients.
UT Health San Antonio launches a National Institute on Aging-funded rapamycin trial with 84 older adults—one of the largest longevity-focused clinical studies to date. The shift: from off-label speculation to evidence-based dosing.
Human Longevity Inc. partners with LEV Foundation to study blood from centenarians and supercentenarians using multi-omic analysis — seeking biomarkers that explain why some people age far more slowly.
The U.S. government's ARPA-H launches the PROSPR program: $144M over five years to identify early aging biomarkers and run the first clinical trials explicitly aimed at extending healthy lifespan.